Dr. Levi Garraway is an Associate Professor of Medicine in the Department of Medical Oncology at the Dana-Farber Cancer Institute, Harvard Medical School. Dr. Garraway is also a faculty member of Dana-Farber’s Center for Cancer Genome Discovery and a Senior Associate Member of the Broad Institute, where he leads several large cancer genome analyses and functional genomics efforts in the Broad Cancer Program.
Dr. Garraway leads a 16-member investigative team in cancer genomics at Dana-Farber and the Broad Institute. His research has informed several gene targets and “druggable” pathways relevant to the genesis and therapeutic vulnerabilities of melanoma and other malignancies. Dr. Garraway’s group developed OncoMap, a platform for systematic cancer mutation profiling that has inspired multiple personalized cancer medicine efforts across the U.S. and beyond.
Dr. Garraway has been the recipient of several awards and honors, including the Minority Scholar Award from the American Association of Cancer Research, the Partners in Excellence Award from the Massachusetts General Hospital, and the Career Award in the Biomedical Sciences from the Burroughs-Wellcome Fund. In the fall of 2007, Dr. Garraway was awarded one of the first prestigious New Innovator Awards from the National Institutes of Health, worth $1.5 million over five years. The Innovator Awards were given to the top 29 scientists from over 2200 applicants nationwide. In 2009, Dr. Garraway was inducted into the American Society for Clinical Investigation.